As cancer survival rates improve through targeted therapies like immunotherapies and antibody-drug conjugates, the medical community faces a growing challenge in recording and managing long-term treatment toxicities. Current reporting frameworks, such as the Common Terminology Criteria for Adverse Events (CTCAE), often fail to capture the chronic, low-grade, or functional impacts of these life-extending treatments on patient quality of life.
The Limitations of Current Toxicity Reporting
Modern cancer care has shifted toward precision medicine, yet the tools used to track patient safety remain rooted in older, acute-focused models. The CTCAE system primarily tracks acute adverse events but does not adequately account for the duration of these side effects or their cumulative impact on daily functioning.
For many patients, "low-grade" toxicities—such as persistent rashes or diarrhea—can become functionally and psychologically debilitating when they last for years. Because quality-of-life data are frequently published years after the initial clinical trial results and drug approval, current patients often lack a full understanding of the long-term trade-offs before beginning a new therapy.
Why Informed Consent Requires Evolution
The lack of comprehensive toxicity data complicates the process of informed consent. In clinical practice, if a drug’s potential for chronic, non-CTCAE-defined side effects is unknown or underestimated, patients cannot fully weigh the risks of treatment.
Real-world experience with therapies like the bispecific antibody amivantamab in lung cancer demonstrates that the full scope of skin toxicities often only emerges once a broader, more diverse patient population is exposed to the drug. Furthermore, historical disparities in clinical trial enrollment mean that certain populations—including those with specific genetic backgrounds or comorbid conditions—may face unexpected toxicities that were not identified during the initial study phases. Addressing these gaps requires the integration of real-world evidence and more frequent updates to patient-reported outcome questionnaires.
Bridging Disciplinary Silos
Effective management of modern cancer therapies requires moving beyond traditional medical siloing. Specialized side effects, such as cytokine-release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy or immune-related adverse events from checkpoint inhibitors, require coordinated, cross-disciplinary oversight.
Several initiatives are currently working to harmonize these efforts:
- Cross-disciplinary working groups: These bodies develop guidelines for identifying and treating rare syndromes caused by immune effector cell-based therapies.
- Registry-based monitoring: The Side Effect Registry Immuno-Oncology serves as a resource for tracking immune-related side effects across different cancer types.
Future Directions for Patient-Centered Oncology
To improve outcomes for long-term survivors, the oncology field must prioritize the integration of patient perspectives early in the drug development lifecycle. This involves moving toward "tissue-agnostic" reporting standards that account for the unique mechanisms of action of novel drug classes.
As the pace of oncology innovation accelerates, the medical community must transition from a reactive model of toxicity management to one that proactively captures functional and emotional well-being. By updating reporting criteria to include the duration and daily impact of side effects, clinicians can better ensure that the benefits of extended survival are matched by a high, sustainable quality of life.
Worth a look